Improving function in Age-Related Macular Degeneration: Design and methods of a randomized clinical trial

Contemporary Clinical Trials

Volumn 32, Issue 2, 2011, Pages 196-203

  Rovner, Barry W ^a   Casten, Robin J ^a   Hegel, Mark T ^b   Massof, Robert W ^c   Leiby, Benjamin E ^a   Tasman, William S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Age Related Macular Degeneration; Clinical trial; Depression; Vision function

Indexed keywords

ARTICLE; ATTENTION; FUNCTIONAL ASSESSMENT; HUMAN; OUTCOME ASSESSMENT; PROBLEM SOLVING; PROBLEM SOLVING THERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUPPORTIVE THERAPY; TREATMENT OUTCOME; VISUAL ACUITY;

ACTIVITIES OF DAILY LIVING; AGED; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PATIENT COMPLIANCE; PROBLEM SOLVING; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF EFFICACY; TREATMENT OUTCOME; VISION TESTS; VISION, OCULAR;

EID: 79551542768     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.10.008     Document Type: Article

References (47)

1. Fine S.L., Berger J.W., Maguire M.G., et al. Age-related macular degeneration. N Eng J Med 2000, 342:483-492.
2. The Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004, 122:564-572.
3. Rein D.R., Wittenborn J.S., Zhang X., Honeycutt A.A., Lesesne S.B., Saaddine J., for the Vision Health Cost-Effectiveness Study Group Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009, 127:533-540.
4. Slakter J.S., Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol 2005, 50:263-273.
5. Szabo S.M., Janssen P.A., Khan K., Potter M.J., M.D., Lord S.R. Older women with age-related macular degeneration have a greater risk of falls: a physiological profile assessment study. J Am Geriatr Soc 2008, 56:800-807.
6. Cruess A., Zlateva G., Xu X., Rochon S. Burden of illness of neovascular age- related macular degeneration in Canada. Can J Ophthalmal 2007, 42:836-843.
7. Evans J.R., Smeeth L., Fletcher A.E. Risk of admission to a nursing home among older people with visual impairment in Great Britain. Arch Ophthalmol 2008, 126:1428-1433.
8. Rosenfeld P., Rich R., Lalwani G. Ranibizumab: phase III clinical trial results. Ophthalmol Clin N Am 2006, 19:361-372.
9. Age-Related Eye Disease Study Research Group A randomized, placebo controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch Ophthalmol 2001, 119:1417-1436.
10. Mangione C.M., Lee P.P., Gutierrez P., Spritzer K., Berry S., Hays R.D. Development of the 25-item National Eye Institute visual function questionnaire (VFQ-25). Arch Ophthal 2001, 119:1050-1058.
11. Reischies F.M., Geiselmann B. Age-related cognitive and vision impairment affecting the detection of dementia syndrome in old age. Br J Psychiatry 1997, 171:449-451.
12. West S.K., Rubin G.S., Broman A.T., Munoz B., et al. How does visual impairment affect performance on tasks of everyday life?. Arch Ophthalmol 2002, 120:774-780.
13. Verbrugge L.M., Jette A.M. The Disablement Process. Soc Sci Med 1994, 38:114-128.
14. Verbrugge L.M., Lepkowski J.M., Imanaka Y. Comorbidity and its impact on disability. Milbank Q 1989, 67:450-484.
15. World Health Organization (2001, December). ICF: introduction. Retrieved 12/20/01, from http://www.who.int/icf/icfthemplate.cfm.
16. Cuijpers P., van Straten A., Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry 2007, 9-15.
17. Mynors-Wallis L.M., Gath D.H., Lloyd-Thomas A.R., Tomlinson D. Randomized control trial comparing problem-solving treatment with amitriptyline and placebo for major depression in primary care. Br Med J 1995, 310:441-445.
18. DeVellis B.N., Blalock S.J., Hahn P.M., DeVellis R.F., Hochbaum G.N. Evaluation of a problem-solving intervention for patients with arthritis. Patient Educ Couns 1988, 11:29-42.
19. Ahles P.A., Seville J., Wasson J., Johnson D., Callahan E., Stukel T.A. Panel-based pain management in primary care: a pilot study. J Pain Symptom Manage 2001, 22:584-590.
20. Perri M.G., Nazu A.N., McKelvey W.F., Shermar R.L., Renjilian D.A., Viegener B.J. Relapse prevention training and problem-solving therapy in the long-term management of obesity. J Consult Clin Psych. 2001, 69:722-726.
21. Mynors-Wallis L., Davies I., Gray A., Barbour F., Gath D. A randomized control trial and cost analysis of problem-solving treatment for emotional disorders given by community nurses in primary care. Br J Psych. 1997, 170:113-119.
22. Williams J.W., Barrett J., Oxman T., et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000, 284:1519-1526.
23. Rovner B.W., Casten R.J., Hegel M.T., Lieby B.E., Tasman W.S. Preventing depression in age-related macular degeneration. Arch Gen Psychiatry 2007, 64:886-892.
24. Law M., Cooper B., Strong S., Stewart D., Rigby P., Letts L. The person-environment-occupation model: a transactive approach to occupational performance. Can J Occup Ther 1996, 63:9-23.
25. Borkovec T., Newman M., Pincus A.L., Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consulting Clin Psych 2002, 70:288-298.
26. Alexopoulos G., Raue P., Arean P., Lytle R. Problem-solving therapy vs. supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatry 2003, 11:46-52.
27. Barrowclough C., King P., Colville J., et al. A randomized trial of the effectiveness of cognitive-behavioral therapy and supportive counseling for anxiety symptoms in older adults. J Consulting Clin Psych 2001, 69:756-762.
28. Perlis R.H., Ostacher M., Fava M., Nierenberg A.A., Sachs G.S., Rosenbaum J.F. Assuring that double-blind is blind. Am J Psych 2001, 167:250-251.
29. Carroll K.M., Rounsaville B.J., Nich C. Blind man's bluff: effectiveness and significance of psychotherapy and pharmacotherapy blinding procedures in a clinical trial. J Consulting Clinical Psych 1994, 62:276-280.
30. Stelmack J.A., Szlyk J.P., Stelmack T.R., et al. Measuring outcomes of low vision rehabilitation with the Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48). Invest Ophthalmol Vis Sci 2006, 47:3253-3261.
31. Massof R.W. A systems model for low vision rehabilitation. I. Basic concepts. Optom Vis Sci 1995, 72:725-736.
32. Massof R.W., Rubin G.S. Vision function questionnaires. Surv Ophthalmol 2001, 45:531-548.
33. Bilsbury C.D., Richman A. A staging approach to measuring patient-centered subjective outcomes. Acta Psychiatr Scand 2002, 106(suppl. 414):5-40.
34. Arnold L.E., Vitiello V., McDougle C., et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psych 2003, 42:1443-1450.
35. Mulsant B., Mazumdar S., Pollock B., et al. Methodological issues in characterizing treatment response in demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1997, 12:537-547.
36. Scott I.U., Schein O.D., West S., et al. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol 1994, 112:329-335.
37. Ware J.E., Nelson E.C., Sherbourne C.D., Stewart A.L. Preliminary tests of a 6-item general health survey: a patient application. Measuring functioning and well-being: the medical outcomes study approach 1992, Duke University Press, Durham. A. Stewart, J. Ware (Eds.).
38. Von Korff M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
39. Lawton M.P., Moss M., Fulcomere M.C., Kleban M.H. A research and science oriented multi-level assessment instrument. J Geront 1982, 37:91-99.
40. Kroenke K., Spitzer R.L., Williams J.B.W. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
41. Kanter J.W., Mulick P.S., Busch A.M., Berlin K.S., Martell C.R. The Behavioral Activation for Depression Scale (BADS): psychometric properties and factor structure. J Psychopathol Behav Assess 2007, 29:191-202.
42. Massof R.W. Application of stochastic measurement models to visual function rating scale questionnaires. Ophthal Epidemiol 2005, 12:103-124.
43. Massof R.W., et al. Visual disability variables. I. The importance and difficulty of activity goals for a sample of low vision patients. Arch Phys Med Rehabil 2005, 86:946-953.
44. Massof R.W., et al. The Activity Inventory: an adaptive visual function questionnaire. Optom Vis Sci 2007, 84:763-774.
45. Massof R.W. An interval-scaled scoring algorithm for visual function questionnaires. Optom Vis Sci 2007, 84:690-705.
46. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Personality Social Psych 1986, 51:1173-1182.
47. Casten R., Rovner B., Lieby B., Tasman W. Depression despite anti-vascular endothelial growth factor treatment of age-related macular degeneration. Arch Ophthalmol 2010, 128:506-507.